Showing results (201-210 of 210) with videos related to
Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 210 results.
Eclinicalmedicine|October 12, 2020
Sarilumab use in severe SARS-CoV-2 pneumoniaElisa Gremese, Antonella Cingolani, Silvia Laura Bosello, et al.Joint Bone Spine|August 2, 2014
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA registerMarco Sebastiani, Maria Grazia Anelli, Fabiola Atzeni, et al.Health Policy (Amsterdam, Netherlands)|April 17, 2025
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.Frontiers in Pharmacology|June 30, 2017
Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational StudySerena Colafrancesco, Roberta Priori, Guido Valesini, et al.Journal of Autoimmunity|October 2, 2021
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohortMariele Gatto, Francesca Saccon, Laura Andreoli, et al.Frontiers in Pharmacology|April 20, 2019
Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment ResponseAntonio Vitale, Giulio Cavalli, Serena Colafrancesco, et al.Journal of Autoimmunity|January 14, 2020
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictorsLuca Quartuccio, Milena Bond, Miriam Isola, et al.Frontiers in Medicine|March 11, 2020
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory OutcomesAntonio Vitale, Giulio Cavalli, Piero Ruscitti, et al.Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2020
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life SettingMariele Gatto, Francesca Saccon, Margherita Zen, et al.Journal of Personalized Medicine|April 28, 2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)Margherita Zen, Mariele Gatto, Roberto Depascale, et al.Pageof 21